ISRCTN12871246已完成未知
Effects of the addition of low-dose pioglitazone to combined flutamide-metformin treatment on endocrine-metabolic and body composition indices in young women with ovarian hyperandrogenism, hyperinsulinism and cardiovascular risk
Hospital Sant Joan de Deu, University of Barcelona (Spain)0 个研究点目标入组 38 人开始时间: 2006年1月9日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 38
研究概览
简要总结
2009 results in https://pubmed.ncbi.nlm.nih.gov/19018783/ (added 08/04/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Age 18 years or more
- •2. Menarche at least three years before inclusion
- •3. Clinical and/or biochemical signs of androgen excess
- •4. Hyperinsulinism
- •5. Dyslipidemia
- •6. Relative hyperneutrophilia, increased C-reactive protein (CRP)
- •7. Normal liver and kidney functions
- •8. Absence of non-classical adrenal hyperplasia due to 21-OH (21-hydroxylase) deficiency
排除标准
- •1. Age less than 18 years
- •2. Pregnancy
- •3. Hyperprolactinemia
- •4. Cushing's syndrome
- •5. Abnormal thyroid function
- •6. Liver or kidney dysfunction
- •7. Glucose intolerance
- •8. Type 1 or type 2 diabetes
- •9. Cutaneous allergy
- •10. Concomitant therapy with agents influencing lipid or carbohydrate metabolism.
- •11. Alcoholism
- •12. Bacterial infections
研究者
相似试验
已完成
2 期
Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.InflammationHypertensionNCT00770497Takeda172
进行中（未招募）
不适用
Effect of Pioglitazone compared to a combination therapy with Ramipril and to a Ramipril monotherapy on low grade inflammation and vascular function in patients with increased cardiovascular risk and an activated inflammationA randomized double-blinded phase II studyon-diabetic hypertensive patients with a hsCRP value > 1.0 mg/L < 10.0 mg/L and pretreated with ACE inhibitors for at least 12 weeks are eligible for study participation.MedDRA version: 8.1Level: LLTClassification code 10003601Term: AtherosclerosisEUCTR2006-004028-35-DETakeda Pharma GmbH
已完成
2 期
Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes MellitusDiabetes MellitusNCT00762736Takeda704
已完成
不适用
A study to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemiaISRCTN78563659Takeda Europe R and D Centre (UK)26
已完成
2 期
A Phase II Study of Pioglitazone for Patients With Cancer of the PancreasCancer of the PancreasNCT01838317University of Texas Southwestern Medical Center14